Sidley represented Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, in its definitive agreement to be acquired by BioCryst Pharmaceuticals, Inc., a global biotechnology company. The transaction values Astria at approximately US$920 million.
More information about the agreement is available here.
The Sidley team was led by partners Rosemary Reilly (Emerging Companies and Venture Capital), John Butler (M&A and Private Equity) and Sally Wagner Partin (M&A and Private Equity). The team also included Joshua Hofheimer, Elizabeth Burns, Dina M.P. Kang, Amanda Patterson, Nicholas Carballo, Sabrina Glavota, and Sophia Iams (M&A and Private Equity); Rebecca Nauta and Emily Ivers (Emerging Companies and Venture Capital); Torrey Cope, Donielle McCutcheon, Julea Lipiz, and Emily Schneider (Healthcare and FDMD); Vadim Brusser, Eric Kauffman, and Emily M. Wajert (Litigation); Jonathan M. Westreich and Iris Wang (Tax); Steven Rutkovsky (Global Finance); Harsh D. Deshmukh (Investment Funds); and Stephanie Y. Lim (Regulatory and Enforcement).
